Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma

Cancer Biology and Medicine

Volumn 9, Issue 2, 2012, Pages 85-89

  Guo, Shan Qi ^a   Zhang, Yi Zhuo ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Epigenomics; Histone deacetylases; Lymphoma; Therapeutics

Indexed keywords

APICIDIN; BELINOSTAT; CD30 ANTIGEN; DEPSIPEPTIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE; MOCETINOSTAT; PANOBINOSTAT; PROTEIN BCL XL; PROTEIN MCL 1; ROMIDEPSIN; STAT PROTEIN; TRICHOSTATIN A; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ALBUMINURIA; ANGIOGENESIS; ANOREXIA; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER REGRESSION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL MOTILITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPERLIPIDEMIA; HYPOCALCEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOMA; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 84876338104     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.02.001     Document Type: Article

References (32)

1. Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010; 3: 5.
2. Hagelkruys A, Sawicka A, Rennmayr M, et al. The biology of HDAC in cancer: The nuclear and epigenetic components. Handb Exp Pharmacol 2011; 206: 13-37.
3. Kim HJ, Bae SC. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3: 166-179.
4. Ocker M. Deacetylase inhibitors-focus on non-histone targets and effects. World J Biol Chem 2010; 1: 55-61.
5. Li K, Luo J. The role of SIRT1 in tumorigenesis. N Am J Med Sci (Boston) 2011; 4: 104-106.
6. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol 2010; 22: 431-436.
7. Gloghini A, Buglio D, Khaskhely NM, et al. Expression of histone deacetylases in lymphoma: Implication for the development of selective inhibitors. Br J Haematol 2009; 147: 515-525.
8. Mehnert JM, Kelly WK. Histone deacetylase inhibitors: Biology and mechanism of action. Cancer J 2007; 13: 23-29.
9. Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010; 62: 18-34.
10. Lee JH, Choy ML, Ngo L, et al. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. PNAS 2010; 107: 14639-14644.
11. Richon VM, Sandhoff TW, Rifkind RA, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-10019.
12. Rosato RR, Almenara JA, Dai Y, et al. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosisinducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2003; 2: 1273-1284.
13. Brodská B, Holoubek A. Generation of Reactive Oxygen Species during Apoptosis Induced by DNA-Damaging Agents and/or Histone Deacetylase Inhibitors. Oxid Med Cell Longev 2011; 2011: 253529.
14. Hidemi Rikiishi. Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells. J Biomed Biotechnol 2011; 2011: 830260.
15. Cotto M, Cabanillas F, Tirado M, et al. Epigenetic therapy of lymphoma using histone deacetylase inhibitors. Clin Transl Oncol 2010; 12: 401-409.
16. Lemoine M, Younes A. Histone deacetylase inhibitors in the treatment of lymphoma. Discov Med 2010; 10: 462-470.
17. Buglio D, Younes A. IHistone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs 2010; 28: S21-7.
18. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 2009; 147: 97-101.
19. Sureda A, Engert A, Browet PJ, et al. Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). J Clin Oncol (Meeting Abstracts) May 2010 vol. 28 no. 15_suppl 8007.
20. Buglio D, Mamidipudi V, Khaskhely NM, et al. The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism. Br J Haematol 2010; 151: 387-396.
21. Shaknovich R, Melnick A. Epigenetics and B-cell lymphoma. Curr Opin Hematol 2011; 18: 293-299.
22. Zain J, O'Connor OA. Targeting histone deacetyalses in the treatment of B-and T-cell malignancies. Invest New Drugs 2010; 28 Suppl 1: S58-78.
23. Watanabe T, Kato H, Kobayashi Y, et al. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 2010; 101: 196-200.
24. Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19: 964-969.
25. Zain JM, Foss F, Kelly WK, et al. Final results of a phase I study of oral belinostat (PXD101) in patients with lymphoma. J Clin Oncol (Meeting Abstracts) 2009; 27 (15S): 8580.
26. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-39.
27. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
28. Stephen S, Morrissey KA, Benoit BM, et al. Inhibition of cellmediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T-cell lymphoma. Am J Hematol 2011; 87: 226-228.
29. Hymes KB. The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10: 98-109.
30. Bates S, Piekarz R, Wright J, et al. Final clinical results of a phase 2 NCI multicenter study of Romidepsin in recurrent cutaneous T-cell lymphoma (molecular analyses included). Blood (ASH annual meeting abstracts) 2008, 112: Abstract 1568.
31. Roncolato F, Gazzola A, Zinzani PL, et al. Targeted molecular therapy in peripheral T-cell lymphomas. Expert Rev Hematol 2011; 4: 551-562.
32. Lee JH, Choy ML, Ngo L, et al. Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2011; 108: 19629-19634.